Trastuzumab deruxtecan

Generic Name
Trastuzumab deruxtecan
Brand Names
Enhertu
Drug Type
Biotech
Chemical Formula
-
CAS Number
1826843-81-5
Unique Ingredient Identifier
5384HK7574
Background

Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...

Indication

In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...

Associated Conditions
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
Associated Therapies
-
Clinical Trials
Related News
pmlive.com
·

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

Daiichi Sankyo signs $300m exclusive licence agreement with Alteogen to develop subcutaneous version of ADC Enhertu, using Alteogen’s hybrozyme technology ALT-B4. Alteogen to receive $20m upfront and up to $280m in milestones and royalties.
pharmabiz.com
·

Daiichi Sankyo & AstraZeneca's Enhertu receives 2024 Prix Galien USA Award for Best ...

Daiichi Sankyo and AstraZeneca awarded 2024 Prix Galien USA for Enhertu, a HER2-directed ADC. Enhertu, developed jointly, is transforming HER2+ solid tumour treatment. The Galien Foundation recognizes impactful FDA-approved treatments, honoring medical innovation.
stocktitan.net
·

Daiichi Sankyo Inks Major Deal for Alteogen's Subcutaneous Drug Delivery Technology

Alteogen Inc. entered an exclusive license agreement with Daiichi Sankyo to use ALT-B4, a novel hyaluronidase, for developing a subcutaneous version of ENHERTU®, a HER2-directed ADC. Alteogen will receive upfront and milestone payments, plus royalties on sales, and will supply ALT-B4 for clinical and commercial use.
prnewswire.com
·

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize ...

Alteogen Inc. and Daiichi Sankyo enter an exclusive license agreement for ALT-B4, enabling subcutaneous ENHERTU® development. Alteogen to receive upfront and milestone payments, plus royalties on sales.
targetedonc.com
·

The Targeted Pulse: A Review of Last Month's FDA Prominent Actions and Key Data

Recent breakthroughs in myelodysplastic syndromes (MDS) include the VERONA and SELECT-MDS-1 trials, potentially shifting MDS treatment. FDA actions in October 2024 included approvals for acalabrutinib, priority review for Enhertu, and Cologuard Plus launch. DESTINY-Breast06 shows Enhertu's potential in HER2-low/ultra-low breast cancer. KEYNOTE-522 demonstrated improved survival with pembrolizumab in early-stage triple-negative breast cancer. LEAP-012 showed significant PFS improvement with lenvatinib/pembrolizumab in intermediate HCC. The 19th Annual NY Lung Cancers Symposium will focus on early-stage lung cancer treatment strategies.

Related Clinical Trials:

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
markets.ft.com
·

ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product

Daiichi Sankyo and AstraZeneca awarded 2024 Prix Galien USA for ENHERTU, a HER2-directed ADC, at American Museum of Natural History in New York.

Related Clinical Trials:

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy